MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

GlycoMimetics Inc

Închisă

SectorSănătate

0.18 -14.29

Rezumat

Modificarea prețului

24h

Curent

Minim

0.17

Maxim

0.2

Indicatori cheie

By Trading Economics

Venit

2.6M

-7.2M

EPS

-0.112

Angajați

4

EBITDA

399K

-5.3M

Dividende

By Dow Jones

Următoarele câștiguri

8 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

13M

Deschiderea anterioară

14.47

Închiderea anterioară

0.18

Sentimentul știrilor

By Acuity

50%

50%

180 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

GlycoMimetics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

25 iul. 2024, 15:11 UTC

Principalele dinamici ale pieței

GlycoMimetics Shares Drop 27% After Restructuring Plan, Job Cuts

Comparație

Modificare preț

GlycoMimetics Inc Așteptări

Consens privind evaluarea

By TipRanks

Cumpărare

1 ratings

1

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.2011 / 0.21Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

180 / 386 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre GlycoMimetics Inc

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.